poisar

Stock

NeOnc Technologies Holdings, Inc. NTHI

$3.21-7.23%

Overview

NTHI market data

Price History

NTHI price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.20
Diluted earnings per share over the trailing twelve months.
Beta
2.93
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-48,876.3%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.01 – $12.99
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $90.8M · P/S 1,134.52.

Company News

10 captured
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Aug 14, 2026, 5:06 PM
8-K filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)SEC EDGAR · Aug 13, 2026, 9:21 PM
NeOnc shares are trading lower. The company announced topline results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.Benzinga · Aug 12, 2026, 4:56 PM
Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Aug 12, 2026, 12:25 PM
NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDABenzinga · Aug 12, 2026, 12:03 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga · Aug 12, 2026, 11:55 AM
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data ReadoutGlobenewswire Inc · Aug 10, 2026, 1:15 PM
NeOnc Technologies Q2 EPS $(0.58) Misses $(0.15) EstimateBenzinga · Aug 10, 2026, 1:01 PM
NeOnc Technologies Announces August 12 Conference Call To Present Topline Phase 2a Results From NEO100-01 Trial Of Intranasal NEO100 In IDH1-Mutant GliomaBenzinga · Aug 10, 2026, 12:32 PM
NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July MeetingBenzinga · Jul 15, 2026, 1:03 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock